{
    "clinical_study": {
        "@rank": "135979", 
        "arm_group": [
            {
                "arm_group_label": "Carmustine Sustained Release Implant", 
                "arm_group_type": "Experimental", 
                "description": "For subjects in this group, they will accept intracranially implanted carmustine intraoperatively."
            }, 
            {
                "arm_group_label": "Tumor Resection Surgery", 
                "arm_group_type": "Sham Comparator", 
                "description": "For subjects in this control group, they accept no implants while gliomas maximally be resected."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the safety and efficacy of intracranially implanted\n      Carmustine in the treatment of patients with primary malignant glioma."
        }, 
        "brief_title": "Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anaplastic Astrocytoma", 
            "Anaplastic Oligodendroglioma", 
            "Anaplastic Oligoastrocytoma", 
            "Glioblastoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Glioblastoma", 
                "Oligodendroglioma", 
                "Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Malignant gliomas recur mostly 2 cm within originated area. Local therapies therefore become\n      particular important. Gliadel wafer developed in the States and marketed in the developed\n      countries is an example of such treatments. The product in this study, Carmustine Sustained\n      Release Implant (CASANT), is similar to that of Gliadel wafer as for the API(Active\n      Pharmaceutical Ingredient), but different as for drug delivering system. As required, the\n      preliminary clinical studies were conducted in China. Based on the results of phase I/II ,\n      8-10 wafers containing given dose of BCNU will be administered intracranially in this phase\n      III to the tumor resected cavity to investigate the safety and efficacy in the treatment of\n      primary malignant glioma in 236 patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmation of high grade glioma(WHO III or above)by frozen or squash preparation;\n\n          -  Patients must be 18 to 70 years old, signed ICF;\n\n          -  At least 4 weeks after previous chemotherapy (6 weeks since nitrosoureas);\n\n          -  KPS \u2265 60;\n\n          -  Unilateral, Supratentorial, solitary lesion and not crossing the midline\n\n          -  No obvious important organ dysfunction: Hepatic function:Serum total bilirubin \u22641.5\n             times upper limit of laboratory normal; Aspartate aminotransferase (AST) and/or\n             Alanine aminotransferase (ALT)\uff1c2.5 times upper limit of laboratory normal; Renal\n             function:Serum creatinine \u22641.5 times upper limit of laboratory normal;\n\n          -  Not Pregnant or lactating for women of childbearing potential.\n\n        Exclusion Criteria:\n\n          -  Underwent cytoreductive surgery(excluded stereotactic biopsy);\n\n          -  With chemotherapy or brain radiotherapy history;\n\n          -  Tumor located at ventricular system, Open ventricle tumor cavity postoperatively;\n\n          -  Concomitant with other life-threatening diseases and with life expectancy \uff1c12 months;\n\n          -  Allergic to nitrosourea drugs;\n\n          -  With history of intracranial radiotherapy or implant chemotherapy;\n\n          -  With serious cardiac, pulmonary, hepatic and renal dysfunction, poor glycemic\n             control;\n\n          -  Experienced > 3 times of Large epilepsy within one month preoperatively.\n\n          -  Investigators thought unsuitable for enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "236", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656980", 
            "org_study_id": "LJ-Glioma 3. 3.0 Version"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carmustine Sustained Release Implant", 
                "description": "As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.", 
                "intervention_name": "Carmustine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Trade name: CASANT", 
                    "Other name: BCNU"
                ]
            }, 
            {
                "arm_group_label": "Tumor Resection Surgery", 
                "description": "For this group, subjects will accept routine tumor resection surgery and place no implant wafers.", 
                "intervention_name": "tumor resection surgery", 
                "intervention_type": "Procedure", 
                "other_name": "blank control group"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carmustine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 2, 2012", 
        "link": {
            "description": "You will see subjects recruitment information when visiting above website.", 
            "url": "http://lanjin.cn"
        }, 
        "location": {
            "contact": {
                "email": "sunyanhui1109@yahoo.com.cn", 
                "last_name": "Yan H Sun, M.D.", 
                "phone": "+86-1360-1389-945"
            }, 
            "contact_backup": {
                "email": "Yujj@lanjin.cn", 
                "last_name": "Jian J Yu, Master", 
                "phone": "+86-15336402751"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100050"
                }, 
                "name": "Beijing Tiantan Hospital Affiliated to Capital Medical University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma", 
        "overall_contact": {
            "email": "sunyanhui1109@yahoo.com.cn", 
            "last_name": "Yan H Sun, M.D.", 
            "phone": "+86-1360-1389-945"
        }, 
        "overall_contact_backup": {
            "email": "yujj@lanjin.cn", 
            "last_name": "Jian J Yu, Master", 
            "phone": "+86-15336402751"
        }, 
        "overall_official": {
            "affiliation": "Beijing Tiantan Hospital", 
            "last_name": "Yan H Sun, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progress Free Survival", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "measure": "Overall Survival Rate at 12 months", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "measure": "Karnofsky Performance Status(KPS)", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "measure": "Quality of Life(QOL)", 
                "safety_issue": "No", 
                "time_frame": "15 months"
            }, 
            {
                "description": "Occurrence rate of adverse event and serious adverse event revealed by laboratory test outcomes including blood routine and chemistry as well as physical examination, vital signs including blood pressure, temperature, respiratory rate , heart rate.", 
                "measure": "Safety of intracranially implanted carmustine after maximal tumor resection", 
                "safety_issue": "Yes", 
                "time_frame": "15 months"
            }
        ], 
        "source": "Shandong Lanjin Pharmaceuticals Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shandong Lanjin Pharmaceuticals Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}